Analysts Set Telix Pharmaceuticals Limited (NASDAQ:TLX) Price Target at $21.00

Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX) have earned a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.00.

A number of equities analysts recently commented on TLX shares. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. Citigroup reiterated a “buy” rating on shares of Telix Pharmaceuticals in a report on Tuesday, January 27th. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research report on Monday, January 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Telix Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Wall Street Zen downgraded shares of Telix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of TLX. Rhumbline Advisers grew its stake in shares of Telix Pharmaceuticals by 117.3% during the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock worth $25,000 after purchasing an additional 1,392 shares during the period. XTX Topco Ltd acquired a new position in shares of Telix Pharmaceuticals during the 4th quarter worth approximately $89,000. OLD Mission Capital LLC purchased a new stake in Telix Pharmaceuticals in the 4th quarter valued at approximately $111,000. Vident Advisory LLC acquired a new stake in Telix Pharmaceuticals during the 4th quarter valued at $204,000. Finally, IHT Wealth Management LLC acquired a new stake in Telix Pharmaceuticals during the 2nd quarter valued at $213,000.

Telix Pharmaceuticals Stock Performance

NASDAQ:TLX opened at $6.71 on Friday. Telix Pharmaceuticals has a 52 week low of $6.28 and a 52 week high of $30.36. The stock’s fifty day moving average is $7.54 and its two-hundred day moving average is $9.31.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.